



Sources of Variability in Vastus Lateralis Fat Fraction Measurements Using MRI in Clinical Trials for Duchenne's Muscular Dystrophy (DMD) Therapy

M. HAMMOND¹, F. ROCHE², J. MARY², M. BERGER¹, F. VINCENT², S. ZABBATINO¹, R. SCHEYER³, M. PETERSEN³, S. HOLLAND¹

¹ Medpace Core Laboratories, Cincinnati, OH, United States; ² Medpace Core Laboratories, Lyon, France; ³ Medpace, Cincinnati, OH, United States



1 INTRODUCTION

- Muscle MR imaging provides important efficacy-response biomarkers for DMD trials¹
- MRI proton density fat fraction (PDFF) is a sensitive and objective key endpoint² for quantifying fat replacement in the vastus lateralis (VL) in DMD
- Central review of images in multi-center trials is recommended to reduce observer variability
- Initial technologist measurement is overread/adjusted by a central physician reviewer in many trials
- This presentation reviews sources and degrees of variability in MRI-PDFF measurements from each stage in the central review process

2 AIMS

- Identify source and degree of variability associated with MRI-PDFF central review of VL fat fraction measurement
- Determine relative contribution of the selection of axial slices to be measured versus the muscle segmentation to the overall variability

3 METHODS

- MRI scans of the lower limb (N=13) optimized for PDFF quantitation^{3,4} were randomly extracted from an anonymous clinical trial data repository.
- VL was segmented from T1-weighted images in 3 axial slices, centered at the midpoint of the VL by 2 independent technologists
- Segmentation contours were corrected or confirmed by 2 independent physicians
- Segmentation from T1-weighted images applied to the PDFF map to calculate the average fat fraction in the VL from those 3 slices




Fig. 1: Computation of Fat Fraction. A) T1-weighted MRI of lower limb B) VL segmented by physician overread in T1-weighted images C) Fat fraction measured from PDFF map

- Read variability was assessed using an intraclass correlation coefficient (ICC) based on a single rating, absolute agreement, 2-way random-effects model (ICC [2,1]), Bland-Altman plots, and minimum detectable change (MDC) estimates for the following:
 - Inter-technologist variability
 - Inter-technologist variability in a subset (Overlap Subset; N=8) where fat fraction was calculated using only the overlapping slices between technologists
 - Inter-physician variability with the same technologist
 - Intra-physician variability with different technologists

4 RESULTS

- Overall reproducibility of VL fat fraction measurement was excellent

Table 1: Summary of statistical measurements of variability

	N	ICC (2,1) (95% CI)	SEM (%)	MDC (%)
Inter-technologist	13	0.972 (0.914 - 0.991)	0.853	2.37
Inter-technologist (overlap subset)	8	0.973 (0.883 - 0.994)	0.903	2.50
Inter-physician (1 technologist)	13	0.996 (0.983 - 0.999)	0.321	0.89
Intra-physician (2 technologists)	13	0.972 (0.917 - 0.992)	0.844	2.34

N = sample size, CI = confidence interval, SEM = standard error of measurement, MDC = minimum detectable change

- The use of a single technologist results in a minimum detectable difference for fat fraction of <1%




Fig. 2: Bland-Altman plot of inter-technologist variability (blue) and overlap sub-set of inter-technologist variability (green) showing mean difference (dashed) and 95% limits of agreement (dotted)

- Restricting the analysis to only overlapping slices between the technologists did not improve variability




Fig. 3: Bland-Altman plot of inter-physician variability with the same technologist (blue) and intra-physician variability with different technologists (green) showing mean difference (dashed) and 95% limits of agreement (dotted)

- The physician overread of the segmentation does not correct for the inter-technologist variability

5 CONCLUSIONS

- The greatest source of variability in VL fat fraction measurement is the initial technologist contour, which is dominated by the effect of differences in segmentation rather than in slice selection

6 REFERENCES

1. FDA Center for Drug Evaluation and Research. Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry. 2018; FDA-2015-D-1884
2. Burakiewicz J, et al. *J Neurol.* 2017; 264(10): 2053–67. doi: 10.1007/s00415-017-8547-3
3. Berglund J, et al. *Magn Reson Med.* 2017 Sep;78(3):941-9. doi: 10.1002/mrm.26479
4. Yu H, et al. *Magn Reson Med.* 2008 Nov;60(5):1122-34. doi: 10.1002/mrm.21737

7 CONTACT

Tel: +1 513 579 9911 (ext. 16480)
E-mail: m.hammond@medpace.com
www.medpace.com

